Results of a Phase I study of the novel Poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in solid tumors and lymphoma have just been published in Cancer Research (doi:10.1158/0008-5472.CAN-11-1227).
Researchers at the University of Chicago and colleagues have identified two variants on chromosome 6q21 that are associated with second malignant neoplasms (SMNs) in survivors of pediatric Hodgkin’s lymphoma. The SMNs are linked to radiation therapy used to treat the pediatric cancer.
Researchers have found that patients with early, localized prostate cancer benefit from short-term androgen-deprivation therapy (ADT) for 4 months prior to and during radiotherapy, and that the addition of ADT increases overall survival and decreases mortality.
Dapagliflozin, the experimental diabetes medication being developed by Bristol-Myers Squibb and AstraZeneca was found to raise the risk of both bladder and breast cancers. The data were presented at the American Diabetes Association Meeting in San Diego, Calif. at the end of June.
Scientists at the Center for Translational Pathology and the department of urology at the University of Michigan Medical School have developed a new noninvasive urine test for prostate cancer that may be able to stratify patients by risk.
Researchers at the Institute for Cancer Research (ICR) in London, driven by the unmet need of personalized cancer treatments for a greater subset of tumors have identified genes in breast tumor cells that sustain and grow the tumors that are potential targets for drug development.
A fairly simple and inexpensive fecal occult blood test (FOBT) that detects blood cells in a person's stool sample has been found to be an effective way to screen for colon cancer. The prospective, 2796 asymptomatic participants from Taiwan participated in the study that was published only on August 2, 2011 in the Canadian Medical Association Journal (DOI:10.1503/cmaj.101248).
With the continuing increase in the utilization of smartphone applications (apps), the Food and Drug Administration (FDA) has decided to jump on the bandwagon. The goal for the FDA is to provide accurate and up to date information for consumers and patients, partly to address the increasing number of ‘health’ applications that may not always be accurate or from reliable sources.
Scientists at the University of British Columbia have found that histone-modifying genes are often mutated in non-Hodgkin’s lymphoma (NHL).
Using in vitro techniques and mouse models, scientists at the University of Chicago Department of Medicine and colleagues have demonstrated that downregulation of PTEN in epidermal keratinocytes predisposes skin to ultraviolet B (UVB)-induced tumorigenesis.